The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock Newsletter
Array BioPharma Inc. (ARRY)

Array BioPharma is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small-molecule drugs to treat patients with cancer. Co.'s wholly-owned clinical stage drugs include: Binimetinib, a MEK inhibitor for cancer; Encorafenib, a BRAF inhibitor for cancer; Filanesib, a Kinesin spindle protein, inhibitor for multiple myeloma; and ARRY-797, a p38 inhibitor for Lamin A/C-related dilated cardiomyopathy. In addition, as of June 30 2015, Co. had 10 partner-funded clinical programs including Selumetinib, a MEK inhibitor for cancer with AstraZeneca, PLC, and Ipatasertib/GDC-0068, a AKT inhibitor for cancer with Genentech, Inc.

ARRY SEC Filing Email Alerts Service

Company Name:  Array BioPharma Inc.
Sector:  Biotechnology
Number of ETFs Holding ARRY:  21
Total Market Value Held by ETFs:  $26.94M
Total Market Capitalization:  $554.00M
% of Market Cap. Held by ETFs:  4.86%
July 30, 2016    3:19 AM Eastern

If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Quotes delayed 20 minutes

Strong Buy (4.00 out of 4)
92nd percentile
(ranked higher than approx. 92% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Array BioPharma Inc. (ARRY) Page | The Online Investor | | Copyright © 1998 - 2016, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.